Eyelid Dermatitis
Conditions
Brief summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Interventions
Upadacitinib 15mg daily
Sponsors
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Individuals age 18-70 years old with eyelid dermatitis for at least two months * Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) * Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib. * Willing and able participants that provide informed consent * Willing and able participants that comply with study activities
Exclusion criteria
* Self-reported history of allergic response to upadacitinib * Subject with self-reported history of heart disease, stroke, or neurological conditions * Currently taking topical medications for eyelid dermatitis within one week of starting study drug * Women who are pregnant, nursing, or who may become pregnant during the study * Non-English-speaking subjects * Patients with an active serious infection * Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment. * Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb\<8g/dL, ALC\<500 cells/mm3 and ANC \<1000 cells/mm3 * Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in Investigator Global Assessment (IGA) | 12 weeks | Reduction in baseline IGA score at week 12 compared to week 0 |
Countries
United States
Contacts
Primary ContactDermatology CTU
Outcome results
None listed